Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma

Cytotherapy

Volumn 13, Issue 10, 2011, Pages 1259-1268

  Akkök, Çiǧdem Akalin ^a   Hervig, Tor ^a,b   Stamnesfet, Siren ^a   Nesthus, Ingerid ^b   Melve, Guro K ^a   Lassalle, Philippe ^c   Bruserud, Øystein ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

angiogenesis; cytokines; hepatocyte growth factor; stem cell harvesting

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CELL MARKER; CYTOKINE; ENDOCAN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR 2; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; APHERESIS; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER THERAPY; CELL THERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RESPONSE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MALE; MICROVASCULAR ENDOTHELIAL CELL; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPHERESIS;

EID: 80053179738     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.605117     Document Type: Article

References (26)

1. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H, et al. European Group for Blood and Marrow. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Defi nitions and current practice in Europe. Bone Marrow Transplant. 2006;37:439-49.
2. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K, et al. Joint Accreditation Committee of the International Society for Cellular Therapy; European Group for Blood and Marrow Transplantation. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant. 2009;43:275-91.
3. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-5.
4. Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis: Role of the microenvironment. Clin Exp Met. 2009;26:51-60.
5. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996; 41:177-85. (Pubitemid 26360147)
6. Akk ök CA, Liseth K, Nesthus I, Lø k eland T, Tefre K, B ruserud O, et al. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation. Transfusion. 2008;48:877-83. (Pubitemid 351614914)
7. Liseth K, Ersvae r E, Abrahamsen JF, Nesthus I, Ryningen A, Bruserud Oslash; Long-term cryopreservation of autologous stem cell grafts: A clinical and experimental study of hematopoietic and immunocompetent cells. Transfusion. 2009;49:1709-19.
8. Bechard D, Meignin V, Scherpereel A, Severine Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the secreted form of endothelial-cell- specifi c molecule 1 by specifi c monoclonal antibodies. J Vasc Res. 2000;37:417-25.
9. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O. In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs. 2008;17: 1623-33.
10. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-73
11. Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: Further evidence for a role of platelets in tumour angiogenesis. Ann Med. 2004;36:273-7. (Pubitemid 38789281)
12. Seidel C, Bø r set M, Turesson I, Abildgaard N, Sundan A, Waage A for the Nordic Myeloma Study Group. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood. 1998;91:806-12.
13. Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol. 2002;119:672-6. (Pubitemid 35366207)
14. Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, et al. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res. 2004;10:6686-94. (Pubitemid 39346566)
15. Hov H, Tian E, Holien T, Holt RU, Vå t sveen TK, Fagerli UM, et al. c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol. 2009;82:277-87.
16. Pour L, Svachova H, Adam Z, Almasi M, Buresova L, B uchler T, et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol. 2010;89:385-9.
17. Fujii K, Ishimaru F, Kozuka T, Matsuo K, Nakase K, Kataoka I, et al. Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Br J Haematol. 2004;124:190-4. (Pubitemid 38122191)
18. Jalili A, Shirvaikar N, Marquez-Curtis LA, Turner AR, Janowska-Wieczorek A. The HGF/c-Met axis synergizes with G-CSF in the mobilization of hematopoietic stem/progenitor cells. Stem Cells Dev. 2010;19:1143-51.
19. Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ, et al. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J. 2005;19:2005 - 7. (Pubitemid 41759746)
20. Glenjen N, Mosevoll KA, Bruserud Oslash; Serum levels of angiogenin, basic fi broblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int J Cancer. 2002;101:86-94. (Pubitemid 34833002)
21. Foss B, Abrahamsen JF, Bruserud Oslash; Peripheral blood progenitor cell grafts contain high levels of platelet-secreted mediators. Transfusion. 2001;41:1431-7.
22. Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, et al. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater. 2008;84:415-21.
23. R yningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res. 2009; 33:779-87.
24. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specifi c molecule-1 (ESM- 1): A potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25-37. (Pubitemid 41752939)
25. Edgren G, Reilly M, Hjalgrim H, Tran TN, Rostgaard K, Adami J, et al. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst. 2008;100: 572-9.
26. Edgren G, Tran TN, Hjalgrim H, Rostgaard K, Shanwell A, Titlestad K, et al. Improving health profi le of blood donors as a consequence of transfusion safety efforts. Transfusion. 2007;47:2017-24 (Pubitemid 47623971)